BiotechTube

Imatinib Mesylate and Nilotinib

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Graft Versus Host Disease

Conditions

Graft Versus Host Disease

Trial Timeline

Dec 24, 2012 → Jul 26, 2017

NCT ID
NCT02891395

About Imatinib Mesylate and Nilotinib

Imatinib Mesylate and Nilotinib is a phase 2 stage product being developed by Novartis for Graft Versus Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02891395. Target conditions include Graft Versus Host Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02891395Phase 2Completed

Competing Products

20 competing products in Graft Versus Host Disease

See all competitors
ProductCompanyStageHype Score
Prograf + Methotrexate + CyclosporineAstellas PharmaApproved
85
AlefaceptAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaApproved
85
Tacrolimus + TacrolimusAstellas PharmaPre-clinical
23
azathioprine + sirolimusAstellas PharmaApproved
85
Itolizumab + EQ001 PlaceboBioconPhase 3
77
EQ001 + EQ001 PlaceboBioconPhase 1/2
41
SHR0302Jiangsu Hengrui MedicinePhase 1
33
AcalabrutinibAstraZenecaPhase 2
52
Aspirin + TicagrelorAstraZenecaApproved
85
SugammadexMerckApproved
85
Efprezimod alfa + Methotrexate + Tacrolimus + PlaceboMerckPhase 2
52
RuxolitinibNovartisApproved
85
Prednisone + Jakavi(ruxolitinib) + PrednisoneNovartisPhase 2
52
PredEverNovartisPhase 2
52
Lifitegrast 5% Ophthalmic Solution + PlaceboNovartisPhase 1
33
CyclosporineNovartisApproved
85
Everolimus + Tacrolimus + Mycophenolic acidNovartisApproved
85
1 + 2NovartisApproved
85
Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte GlobulinNovartisApproved
85

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85